# A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

> **NCT05027802** · PHASE3 · COMPLETED · sponsor: **Ipsen** · enrollment: 61 (actual)

## Conditions studied

- Fibrodysplasia Ossificans Progressiva (FOP)

## Interventions

- **DRUG:** Palovarotene

## Key facts

- **NCT ID:** NCT05027802
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-14
- **Primary completion:** 2024-11-30
- **Final completion:** 2024-11-30
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05027802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05027802, "A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05027802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*